Although the tau kinases DYRK1A and GSK3α/β play key roles in the effects of LPS in the CNS and neurodegenerative diseases such as AD, few studies have investigated the effects of calcium channel blockers on tau kinase activity in vivo (62). The gene discussed is DYRK1A; the disease is Alzheimer disease.